Melasma is a chronic acquired hyperpigmentation disorder that often exerts a psychosocial burden on affected individuals. Although laser- and light-based therapies are pivotal third-line interventions for recalcitrant cases, clinical consensus regarding their comparative efficacy and long-term safety remains inconsistent. This systematic review and meta-analysis aimed to evaluate and synthesize evidence from randomized controlled trials (RCTs) on the efficacy and safety of various laser-based therapies for melasma. A literature search was performed using PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, and Web of Science databases from inception to January 2026. RCTs and split-face comparative studies evaluating laser therapies versus placebo, topical agents, or alternative laser modalities were included. Data synthesis was performed using a random-effects model with Hartung-Knapp adjustment. The primary outcome was the mean difference (MD) in the reduction of the Melasma Area and Severity Index (MASI) score. The certainty of evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Fifty-two studies, involving 1,058 participants, met the inclusion criteria. The overall pooled analysis showed a trend toward clinical improvement that was not statistically significant (MD: 0.70; 95% CI: -0.55, 1.95; p = 0.2682). Subgroup analysis by laser technology revealed that low-fluence Q-switched Nd:YAG (QSNY) (1064 nm) lasers provided a statistically significant reduction in melasma severity (MD 1.47; 95% CI: 0.08 to 2.85, p < 0.05), while picosecond lasers (MD -0.11; 95% CI: -0.79 to 0.57) and fractional lasers (MD 0.94; 95% CI: -0.84 to 2.71) did not significantly outperform control groups. Statistical heterogeneity was high across the evidence (I² = 96.2%). The overall certainty of evidence for the primary outcome was very low because of the lack of blinding and the high inconsistency. No serious adverse events were reported, although minor complications, such as transient erythema and localized burning, were common. Low-fluence QSNY laser therapy is an effective adjunctive modality for melasma management. However, due to high recurrence rates and variability in outcomes, it should be integrated into a multi-modal approach alongside strict photoprotection and topical depigmenting agents. Future research should prioritize the long-term follow-up and standardization of laser parameters across different skin phenotypes.
Congenital diaphragmatic hernia (CDH) is a rare but critical surgical disorder that can be managed using either open or thoracoscopic surgical approaches. However, the optimal approach remains a topic of debate. This study aimed to evaluate the efficacy and safety of thoracoscopic repair compared to open repair in patients with CDH. An extensive literature search was conducted across four databases (PubMed, Web of Science, Scopus, and Cochrane Library) from inception to May 2024, including all relevant studies comparing the two surgical modalities. Key outcomes assessed were hospital stay duration, operation time, mortality, and recurrence. Categorical outcomes were analyzed using the risk ratio (RR) with 95% confidence intervals (CI), while continuous outcomes were analyzed using the mean difference (MD) with 95% CI. Data analysis was performed using Review Manager (RevMan, Version 5.3). A total of 35 studies involving 1,680 individuals with CDH were included in our analysis. The pooled results revealed that thoracoscopic repair was associated with a shorter hospital stay (MD=-6.80, 95% CI [-9.39, -4.21], p< 0.0001) but a longer operation time (MD=23.30, 95% CI [7.22, 39.38], p=0.005) compared to the open approach. Additionally, thoracoscopic repair demonstrated lower mortality rates (RR=0.43, 95% CI [0.24, 0.76], p=0.004) but higher recurrence rates (RR=2.24, 95% CI [1.56, 3.21], p<0.0001) than open repair. Our findings suggest that thoracoscopic repair offers shorter hospital stays and lower mortality rates but involves longer operation times and higher recurrence rates compared to the open approach. These results highlight the need for further large, multicenter, randomized controlled trials to validate our findings and guide clinical decision-making.
congenital diaphragmatic herniathoracoscopic repairopen surgical repairminimally invasive surgery
Gut microbiome-targeted therapies have shown promise in promoting the outcomes of metabolic inflammation-related disease management. This review aims to assess the effectiveness of microbiome-targeted interventions and pinpoint the most promising therapies for clinical implementation. Following the PRISMA 2020 standards, we searched four main databases: PubMed, EMBASE, Scopus, and the Cochrane Library. We integrated medical subject headings (MeSH) and free-text keywords search pertinent to gut microbiome-targeted interventions, along with related outcomes such as inflammation and insulin resistance. English studies were conducted on primary adults with a metabolic disease diagnosis or deemed a high risk, and were mandated to report at least one outcome pertinent to metabolic health or systemic inflammation. To assess the risk bias, data were extracted, and the Cochrane Risk of Bias (RoB) 2.0 tool was employed. Fifteen studies fulfilled the inclusion criteria. A narrative synthesis was conducted. We found that probiotics significantly enhanced insulin resistance (HOMA-IR), reduced circulating endotoxin levels, decreased visceral fat, BMI, and fat mass, and increased beneficial taxa with obesity-associated bacteria reduction. However, inconsistent outcomes were shown for lipid parameters. Prebiotic therapies showed significant decreases in fasting glucose in overweight people, and insulin levels and HOMA-IR in patients with metabolic syndrome, enhanced anti-inflammatory effects (31% C-reactive protein (CRP) reduction, decreased interleukin (IL)-6, tumor necrosis factor-alpha (TNF)-α, and lipopolysaccharide (LPS) levels), and promoted butyrate-producing bacteria. Synbiotic interventions showed complementary benefits for glucose metabolism and body composition. Fecal microbiota transplantation (FMT) studies indicated improved insulin sensitivity and donor microbiota engraftment in responders. Fiber-rich diet trials markedly improved HbA1c levels in diabetic and prediabetic individuals. In conclusion, prebiotics demonstrated the most consistent metabolic and anti-inflammatory benefits across multiple parameters. Probiotics showed targeted effects on insulin resistance and body composition but inconsistent lipid outcomes. FMT and synbiotics require further investigation to establish clinical efficacy. This evidence supports prebiotics as a priority intervention for metabolic disease management through microbiome modulation.
Self-monitoring of blood glucose (SMBG) is a widely used strategy in diabetes management, allowing patients to track their glucose levels and make informed decisions regarding diet, medication, and lifestyle adjustments. The effectiveness of SMBG remains debated. Structured SMBG, which involves systematic monitoring with clear guidance, has been suggested to provide greater benefits compared to unstructured SMBG. We aimed to evaluate the effectiveness of SMBG in improving glycemic control among diabetic patients. A systematic search was conducted in PubMed, the Cochrane Library, and Google Scholar. Studies were included if they examined SMBG interventions and reported glycated hemoglobin (HbA1c) as an outcome. Randomized controlled trials (RCTs) and observational studies were assessed for quality using the Cochrane Risk of Bias Tool and the Newcastle-Ottawa Scale. Meta-analysis was performed using Review Manager (RevMan, The Cochrane Collaboration, Copenhagen, Denmark) to calculate mean differences (MD) and 95% confidence intervals (CI). The comprehensive database search yielded 7,667 records, of which 22 articles were selected for review and analysis. The meta-analysis of 22 studies showed that SMBG significantly reduced HbA1c levels compared to no SMBG (MD = -0.32%, 95% CI: -0.44% to -0.20%). Structured SMBG resulted in a greater reduction (MD = -0.25%, 95% CI: -0.41% to -0.09%) compared to unstructured SMBG. In summary, we showed that SMBG is effective in lowering HbA1c, particularly when structured protocols are followed. Healthcare providers should promote structured SMBG, along with patient education, to enhance adherence and optimize glycemic control. Further long-term studies are necessary to evaluate long-term benefits.
self-monitoring of blood glucoseglycemic controldiabetes mellitusHbA1c
This study aims to conduct a thorough analysis of the existing studies to determine how patients with acute cholecystitis (AC) respond to surgical intervention at different times following their diagnosis. To locate studies that met the inclusion criteria, a thorough computerized search of relevant databases was carried out. A comprehensive search was carried out on PubMed, SCOPUS, Science Direct, Cochrane Library, and Web of Science to locate relevant material. Our data included seven trials with 48,747 patients: 40,955 in the early laparoscopic cholecystectomy (ELC) group and 7,792 in the delayed laparoscopic cholecystectomy (DLC) group. More than half of the participants (27,687, 56.8%) were female. ELC was found to be safe regardless of when symptoms first appeared, challenging previous assumptions that surgery should be delayed during the initial symptomatic period. Mortality rates for ELC were consistently low, ranging from 0% to 3.9% in all groups, while complication rates varied from 3.5% to 12.5% in all groups as well. Although DLC is still considered safe, the likelihood of complications such as bile duct damage and surgical site infections appeared to increase, particularly in patients who underwent surgery more than three days after the diagnosis of cholecystitis. It is important to note that ELC refers to surgery performed within the first three days after diagnosis, while DLC refers to surgery performed after three days. The systematic review reveals that ELC is a secure and successful remedy for sudden cholecystitis, offering superior outcomes compared to DLC. ELC is associated with lower complication rates, reduced hospital stays, and minimal mortality, suggesting it should be the preferred approach in most cases (performing the surgery within the first three days following the diagnosis of AC). While DLC remains a viable option, particularly for certain patient populations, it carries a higher risk of complications and prolonged recovery times.
acute cholecystitistiming of surgeryearly laparoscopic cholecystectomydelayed laparoscopic cholecystectomy
This review aims to clarify the influence of various nutritional approaches in the management of hypertension. An extensive search of databases, namely, PubMed, Cochrane Library, Scopus, and Web of Science, was performed, covering the period from January 2012 to October 2023. We used keywords, such as "hypertension," "nutrition," "nutritional management," "nutrient intake," "dietary strategies," "DASH diet," "Mediterranean diet," and related terms. Hypertension, a grave global health concern, affects more than one billion people worldwide. Lifestyle modifications, including nutritional strategies, are important in non-pharmacological interventions. Dietary patterns, such as the DASH (Dietary Approaches to Stop Hypertension) and Mediterranean diets, which emphasize fruit and vegetable consumption, have demonstrated efficacy in reducing blood pressure. Certain nutrients, such as potassium, calcium, and magnesium, have significant effects on blood pressure. The mechanisms underlying these dietary strategies include vasodilation, improvement in endothelial function, regulation of sodium balance, and mitigation of oxidative stress. However, successful implementation of these strategies can be hindered by various factors, such as adherence challenges, socioeconomic disparities, and cultural preferences. In conclusion, robust evidence supports the effectiveness of nutritional strategies in the management of hypertension. DASH and Mediterranean diets, along with an increased intake of specific nutrients, contribute to blood pressure reduction. Hence, comprehensive lifestyle modifications, with a focus on nutritional changes, are recommended as primary or complementary treatments for hypertension. Addressing the identified barriers could enhance the efficacy and use of these dietary approaches in clinical practice.
Cerebral palsy (CP) is a developmental and physical disorder with different degrees of severity. Since CP manifests itself in early childhood, numerous research studies have concentrated on children with CP. Patients with CP encounter different severity of motor impairments attributed to the damage or disturbance to the fetal or infant developing brain, which begins in early childhood and persists through adulthood. Patients with CP are more prone to mortality compared to the general population. This systematic review and meta-analysis aimed to assess the risk factors that predict and influence mortality in patients with CP. Systematic search for studies assessing the risk factors for mortality in CP patients that were conducted from 2000 to 2023 in Google Scholar, PubMed, and Cochrane Library was performed. R-One Group Proportion was used for statistical analysis and Newcastle-Ottawa Quality Assessment Scale (NOS) for quality appraisal. Of the 1791 total database searches, nine studies were included. Based on the NOS tool for quality appraisal, seven studies were of moderate quality, and two studies were rated as of high quality. The risk factors included pneumonia and other respiratory infections, neurological disorders, circulatory diseases, gastrointestinal infections, and accidents. Pneumonia (OR = 0.40, 95% CI = 0.31 - 0.51), neurological disorders (OR = 0.11, 95% CI = 0.08 - 0.16), respiratory infections (OR = 0.36, 95% CI = 0.31 - 0.51), cardiovascular and circulatory diseases (OR = 0.11, 95% CI = 0.04 - 0.27), gastrointestinal and metabolic causes (OR = 0.12, 95% CI = 0.06 - 0.22), and accidents (OR = 0.05, 95% CI = 0.04 - 0.07) were the risk factors assessed. It was concluded that multiple factors predict the risk of mortality in patients with CP. Pneumonia and other respiratory infections are associated with a high risk of mortality. Cardiovascular and circulatory diseases, gastrointestinal and metabolic disorders, and accidents are strongly linked to mortality in CP patients.